WEST LAFAYETTE, Ind.--(BUSINESS WIRE)-- Endocyte, Inc., a biopharmaceutical company developing targeted small-molecule drug conjugates, announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. The joint book-running managers of the proposed offering will be RBC Capital Markets and Leerink Swann LLC. Wedbush PacGrow Life Sciences and Baird are acting as co-managers for the offering.
A registration statement relating to the common stock has been filed with the SEC but has not yet become effective. The common stock may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This offering shall be made only by means of a prospectus. Once available, a preliminary prospectus relating to these securities may be obtained from RBC Capital Markets Corporation, Attention: Equity Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at 877-822-4089, or from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by telephone at 800-808-7525, ext. 4814. The registration statement may be accessed through the SEC’s website at www.sec.gov.
Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. Endocyte uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging diagnostics, targeting receptors that are over-expressed on diseased cells. For more information, visit www.endocyte.com.
KEYWORDS: United States North America Indiana
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology Pharmaceutical FDA